Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL) will participate in the BTIG 2022 Hybrid Biotechnology Conference in August 2022. The management team will hold in-person one-on-one meetings on August 8 and virtual meetings on August 9. As a clinical-stage biopharmaceutical company, Gracell focuses on developing innovative cell therapies for cancer treatment using its advanced FasTCAR and TruUCAR technology platforms. These aim to address significant challenges in conventional CAR-T therapies, such as long manufacturing times and high costs.

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, July 26, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in BTIG 2022 Hybrid Biotechnology Conference in August 2022.

The Gracell team will conduct one-on-one meetings in person on August 8 and virtually on August 9.

About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART^TM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong 
gracie.tong@gracellbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-btig-2022-biotechnology-conference-301592217.html

SOURCE Gracell Biotechnologies Inc.

FAQ

What is the date of Gracell's participation in the BTIG 2022 conference?

Gracell will participate in the BTIG 2022 Hybrid Biotechnology Conference in August 2022.

When will Gracell hold one-on-one meetings at the BTIG conference?

Gracell will hold in-person one-on-one meetings on August 8 and virtual meetings on August 9.

What technologies does Gracell use for developing cell therapies?

Gracell employs FasTCAR and TruUCAR technology platforms for developing its cell therapies.

What are the main goals of Gracell's therapies?

Gracell aims to develop cancer treatments that overcome challenges like lengthy manufacturing time and high costs associated with traditional CAR-T therapies.

Where can I find more information about Gracell?

More information about Gracell can be found on their official website at www.gracellbio.com.